GLYC GlycoMimetics Inc.

4.45
-0.16  -3%
Previous Close 4.61
Open 4.6
Price To Book 1.08
Market Cap 192,209,696
Shares 43,193,190
Volume 129,538
Short Ratio
Av. Daily Volume 523,421
Stock charts supplied by TradingView

NewsSee all news

  1. GlycoMimetics to Present at Two Upcoming Investor Conferences

    GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that Chief Executive Officer Rachel King will provide a corporate update at two upcoming investor relations conferences in New York, NY in September. Details are as

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due 4Q 2020.
Uproleselan (GMI-1271)
Acute myeloid leukemia (AML) newly diagnosed and refractory - cancer
Phase 3 data failed to meet endpoints - August 2, 2019.
GMI-1070 (rivipansel)
Vaso-occlusive crisis of sickle cell disease
Phase 1 ongoing.
GMI-1271
Multiple myeloma
Proof of concept trial to be initiated 2H 2019.
GMI-1359
Hormone receptor positive metastatic breast cancer
Phase 3 commencement of enrolment announced April 23, 2019.
Uproleselan (GMI-1271) - NCI
Acute myeloid leukemia (AML)

Latest News

  1. GlycoMimetics to Present at Two Upcoming Investor Conferences

    GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that Chief Executive Officer Rachel King will provide a corporate update at two upcoming investor relations conferences in New York, NY in September. Details are as